Imunon, Inc. (issuer named in source: Celsion Corporation) — Form 10-Q summary
Reporting period: Quarter and nine months ended September 30, 2018; filed November 14, 2018. The supplied filing identifies the registrant as Celsion Corporation, not Imunon, Inc.; verify that this is the intended filing.
Business context
Celsion described itself as a development-stage oncology company. Its lead program, ThermoDox, was in a Phase III study for primary liver cancer; GEN-1 was being developed for ovarian and brain cancers. The company reported no significant product revenue and remained dependent on financing and licensing-related receipts.
Financial results and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $375,000 | $375,000 |
| Research and development | $2.19 million | $3.35 million | $9.52 million | $9.87 million |
| General and administrative | $1.96 million | $1.17 million | $7.17 million | $4.29 million |
| Operating loss | $4.02 million | $4.40 million | $16.31 million | $13.79 million |
| Net loss | $4.66 million | $5.67 million | $17.36 million | $15.72 million |
| Net loss per share | $0.26 | $0.70 | $1.00 | $3.04 |
Revenue was entirely licensing revenue; no product revenue was reported. Gross margin was not presented. Q3 net loss narrowed, while nine-month net loss increased year over year. Q3 operating expenses fell 8%, but nine-month expenses rose 18%, mainly reflecting higher G&A and stock-based compensation. Loss per share comparisons were affected by substantially higher weighted-average shares in 2018.
- Cash and investments: $22.0 million, including interest receivable, at September 30, 2018; cash and cash equivalents alone were $3.37 million. Short-term investments were $18.58 million.
- Cash flow: Nine-month operating cash use was $13.08 million; investing cash use was $5.96 million; financing provided $10.96 million. Cash and cash equivalents declined $8.07 million from year-end 2017.
- Liquidity: Current assets were $22.25 million and current liabilities $5.80 million, for reported working capital of $16.7 million.
- Debt: The company drew $10 million under a Horizon loan in June 2018. The September 30 carrying amount was $9.32 million, net of unamortized costs. The loan is secured by substantially all company assets other than intellectual property, bears interest at one-month LIBOR plus 7.625%, and has 24 months of interest-only payments followed by 24 months of principal and interest amortization.
- Equity: Stockholders’ equity was $15.13 million; accumulated deficit was $279.15 million. The company had 17.91 million common shares outstanding at quarter-end.
Material changes and unusual items
- Q3 R&D declined, principally because OPTIMA Study enrollment was completed and CRO costs fell. The company announced it reached its 550-patient enrollment objective in September; its first planned interim efficacy analysis was expected in mid-2019.
- G&A rose substantially, with the filing citing professional fees, personnel costs and higher non-cash stock compensation. Nine-month stock-based compensation was $3.99 million versus $0.95 million a year earlier.
- A $4.51 million non-cash impairment charge reduced the carrying value of acquired in-process R&D related to glioblastoma. A concurrent $4.11 million non-cash gain from reducing the EGEN earn-out liability partly offset the impairment in Q3 results. These valuation changes are not operating cash flows.
- The company entered an Aspire Capital agreement allowing up to $15 million of share sales over 24 months; no shares had been sold under it as of November 13, 2018. It also issued 164,835 commitment shares.
- New Jersey approved the company’s application to sell tax-loss certificates. Management expected approximately $10 million in net proceeds before year-end 2018; this was an expectation, not cash reported as received at September 30.
Outlook, risks and contingencies
Management expected continuing operating losses and estimated that September 30 cash, investments and interest receivable, together with the anticipated NOL-sale proceeds, would fund operations into the fourth quarter of 2020. It also stated that further funding would be needed to advance product candidates and continue operations. The estimate depends on clinical-development costs, timing, financing availability and other factors; the filing does not guarantee the projected runway.
- Clinical and regulatory outcomes remain uncertain. ThermoDox’s earlier Phase III HEAT study missed its primary endpoint; the current OPTIMA study relies on post-hoc subgroup analyses from HEAT, which the filing cautions should be viewed carefully.
- GEN-1’s OVATION II study began dosing in September 2018. The company’s reported earlier OVATION results were from a small study and are not confirmation of efficacy in a larger trial.
- Additional financing may be required and could dilute shareholders. If funding is unavailable, the company may have to delay, reduce or terminate development activities.
- Other material risks include dependence on third-party clinical research organizations and manufacturers, regulatory approval and reimbursement uncertainty, intellectual-property risks, and potential volatility or delisting of the common stock.
- The filing reported no legal proceedings and no off-balance-sheet financing arrangements. Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q is for Celsion Corporation, despite the request naming Imunon, Inc.
- Check whether the anticipated approximately $10 million NOL-sale proceeds were actually received and whether management’s fourth-quarter 2020 runway estimate remained supportable.
- Review OPTIMA’s interim-analysis timing and eventual results, and distinguish prospective trial results from retrospective HEAT subgroup findings.
- Assess the status and costs of GEN-1’s OVATION II program and the implications of the glioblastoma impairment for development priorities and contingent EGEN earn-out payments.
- Track Horizon loan interest, covenants and repayment terms, along with any Aspire Capital share sales, warrant exchanges or other dilution after quarter-end.